TransCode Therapeutics Inc — Cash Flow (NASDAQ:RNAZ)

Financials

Cash from operating activities -5.27 M15.8 M-18.07 M13.3 M 34.89 M Cash from investing activities -251.82 K-100.92 K-35.61 K-21.76 K — Cash from financing activities 25.52 M5 98915.91 M16.4 M 15.48 M Free cash flow -5.52 M15.7 M-18.11 M13.28 M 34.89 M

新闻

TransCode从Unleash获得膀胱癌疗法平台授权

TransCode licenses bladder cancer therapy platform from Unleash

TransCode Therapeutics股价在提交IND修正案后大涨

TransCode Therapeutics股价在有希望的胶质母细胞瘤研究后飙升

TransCode Therapeutics stock soars after promising glioblastoma study

TransCode Therapeutics appoints Jack E. Stover to board of directors

TransCode和Quantum Leap将在2a期临床试验中测试癌症疗法

TransCode and Quantum Leap to test cancer therapy in phase 2a trial

TransCode Therapeutics appoints Michel Janicot as development officer

Transcode Therapeutics修改优先股条款获股东批准

Transcode Therapeutics amends preferred stock terms following shareholder approval

TransCode reports positive safety data from TTX-MC138 phase 1a trial